GB2334577A - Resistance of p53 mutant cancer cells to cytoxic effects of (chemo)therapeutic agents involving assay of cyclin D1 protein - Google Patents

Abstract

The measurement of the resistance of p53 cancer cells to the cytotoxic effects of chemotherapeutic agents comprises assay of a sample comprising p53 mutant cells, or an extract therefrom, for the level of cyclin D1 protein. The agent may be a platination agent, especially CDDT (cis-diaminedichloro-platinum). The level of cyclin D1 may be determined either from the mRNA thereof, especially involving a probe therefor, or by contacting the sample with a labelled antibody against cyclin D1 protein. Mutant cells may be identified using an antibody against mutant p53. A kit, for performing the process, is described.

Description

MEASURING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS The present application concerns methods of selecting the most appropriate therapy for patients suffering from cancer. The application is particularly concerned with measuring the resistance of cancer cells to chemotherapeutic agents.

Although radiotherapy and chemotherapy have been responsible for curing many people of cancer in the latter half of this century, there still remain a large number of tumours which either show little response to treatment, or respond initially only to recur later. In particular, women treated for ovarian cancer with platinating agents often show encouraging initial responses to chemotherapy (which in the UK usually involves the use of cisdiamminedichloroplatinum as the drug of first choice), but by 5 years after diagnosis, 2/3 of them have succumbed to their disease. Similarly lung cancer patients may respond favourably to combination chemotherapy regimens containing cisdiamminedichloroplatinum (CDDP) at the outset of treatment but very few experience long term survival. A better understanding of the mechanisms underlying the responsiveness of cancers to CDDP, could help predict which patients are most likely to benefit from CDDP or whether alternative cytotoxic agents such as Taxol or different therapies such as radiotherapy might be appropriate. Understanding treatment response mechanisms also holds the possibility of selectively modulating these mechanisms to improve the treatment of human cancer using CDDP.

It has become increasingly apparent that certain oncogenes and tumour suppressor genes may not only be implicated in carcinogenesis, but can also influence the sensitivity of malignant cells to therapeutic agents. Attempts have therefore been made to use these and other genes to try and predict the therapeutic response of human cancer to the presently available treatment modalities such as radiotherapy and/or cytotoxic chemotherapy. Research up te the present time, however, has generally attempted to only examine the expression of single tumour related genes as methods of predicting therapeutic response. Research in the public domain has suggested that mutations in the p53 tumour suppressor gene, which can be found in around 50% of common cancers such as those of the breast, lung and ovary, are associated with resistance to treatment with cytotoxic drugs or radiation. Despite a considerable body of work, however, there are at present no successful clinical tests by which the detection of mutations in the p53 gene alone can be used to predict with an acceptable degree of certainty whether or not a patient's cancer is likely to respond to chemotherapy with, for example, platinating agents or the newer cytotoxic agents such as Taxol.

The expression of single genes alone on the response of human cancer cell lines to treatment with cytotoxic drugs such as cis diamminedichloro-platinum (CDDT) has been studied in human in vitro cell lines because these present a model system relevant to the response of human cancer in the clinic. In particular, they exhibit the range of sensitivities to cytotoxic drugs and ionising radiation usually encountered in the clinic. Discoveries in human in vitro cell lines, therefore, have a strong possibility of being able to be translated into clinically useful tests for how well cancers may be expected to respond to treatment. The protein products of the cyclin D1 and B1 genes and their respective cyclin-dependent kinase partners CDK4 and CDK1 have been studied. Cyclin Dl and CDK4 control the progress of cells through the cell cycle checkpoint between G1 and S-phase (the phase of DNA synthesis). Cyclin B1 and CDK1 control the cell cycle checkpoint just before mitosis. The expression of cyclin D1 protein in a series of 16 human cancer cell lines has been shown to be related to their intrinsic resistance to the cytotxic drug cis-diamminedichloroplatinum (II) (CDDP) (Warenius et al., 1996) . Cyclin D1 protein levels, however, showed no relationship with radiosensitivity, another treatment modality. The relationship between cyclin D1 and CDDP resistance is not, however, strong enough on its own to provide the basis of clinically useful predictive assays.

Thus, there are no indicators that measuring the mutational status or levels of expression of the protein products of single oncogenes, proto-oncogenes or tumour suppressor genes in human cancer cells would be able to provide the basis of a reliable clinical test for whether clinical tumours were likely to respond to treatment with chemotherapeutic agents, including platination agents and CDDP.

Invention: This invention provides methods of predicting whether human cancer cells are likely to respond to anticancer therapy agents (chemotherapeutic agents, such as platination agents e.g. CDDP) by contemporaneously measuring the properties of two or more cancer-related genes. Moreover the co-relationship between certain independently expressed cancer genes identified in this invention also provide previously undescribed targets against which to potentially direct therapy that is more cancer specific.

In particular, this application provides a method for measuring the resistance of p53 mutant cancer cells to the cytotoxic effects of chemotherapeutic agents, which method comprises testing a sample comprising p53 mutant cells or an extract therefrom for the abundance of cyclin D1 protein. This application also provides a kit for measuring the resistance of p53 mutant cancer cells to the cytotoxic effects of chemotherapeutic agents, which method comprises a means for testing for the abundance of cyclin D1 protein and a means for identifying p53 mutant cells.

Thus, this application specifically deals with measuring the levels of Cyclin D1 protein, in cells whose p53 mutational status has been determined (e.g. by DNA sequencing) to determine the resistance of a tumour to (for example) cisdiamminedichloroplatinum (CDDP). High cyclin D1 levels or high cyclin D1 expression together with p53 mutation is strongly associated with resistance to CDDP in human cancer cells.

The present invention will be described in further detail by way of example only with reference to the accompanying drawings, in which: Figure 1A shows the relationship between the level of cyclin D1 protein and relative resistance to CDDP in mutant p53 cell lines; and Figure 1B shows the corresponding relationship in wild-type p53 cell lines.

Human cancer cell lines with a combination of p53 mutation and high levels of expression of the cyclin D1 protein are resistant to CDDP. This finding carries important clinical possibilities with regard to providing a potentially new parameter for predictive assays for CDDP responsiveness or a new target for modulating CDDP responsiveness.

The high correlation of p53 mutations with high cyclin D1 levels or cyclin D1 over-expression also provides a potential target for drug development. Efforts are being made to develop drugs against mutant forms of p53 and independantly, against cyclin D1. Such drugs are likely to be more effective when used together to treat cancers with the above p53 mutations and cyclin D1 overexpression. Such drugs might also be used in combination with other agents such as CDDP as potentiators of its effectiveness.

A Dual Parameter Test for CDDP Resistance Using p53 Mutational Status and Cyclin D1 Protein Expression Fig. 1A shows that in p53 mutant human cell lines there is a strong relationship between the level of cyclin D1 protein and relative resistance to CDDP as measured by the D0.1 values. The implication is that human cancer cells with p53 mutations and high levels of cyclin D1 protein are unlikely to respond to CDDP and alternative therapy such as Taxol should be considered. It is possible that Taxol sensitivity is not influenced by a combination of p53 mutation and cyclin D1 protein overexpression. The cyclin Dl/p53 mutation test may also detect resistance to other cytotoxic drugs such as etoposide but ionising radiation does not have any relationship to cyclin D1 over-expression in p53 mutant cells. Thus the test will indicate situations where radiation might be a viable alternative to CDDP, or whether other cytotoxic agents might be more appropriate.

A clinical test may be developed for CDDP sensitivity based on the dual measurement of Cyclin D1 protein expression and the presence of mutations in the p53 gene. Cyclin D1 protein is typically measured by Western blotting or immunocytochemistry in a research environment but for diagnostic purposes cheaper and more rapid methods are desirable.

The determination of the mutational status of p53 can be effected by sequencing the genomic locus bearing the gene from the patient or by sequencing the expressed mRNA after conversion to cDNA.

Various nucleic acid sequencing methodologies are available at present, all of which are appropriate for use with this diagnostic assay. The typical method would be based on incorporation of terminating nucleotides into polymerase generated copies of a template, using the method of Sanger et al, 1977. Many alternatives have arisen recently including adaptor sequencing (PCT/US95/12678), ligation based sequencing (PCT/US96/05245), sequencing by hybridisation (A.D. Mirzabekov, TIBTech 12: 27 - 32, 1994) to list a few. Various methods for testing for specific mutations are known in the art, such as the TaqMan assay, oligonucleotide ligase assays, single strand conformational polymorphisms and assays based on hybridisation of template nucleic acids to oligonucleotide arrays.

Because cyclin D1 is a relatively short lived protein under cyclical transcriptional control, it is likely that mRNA levels for cyclin D1 will follow the same pattern as the cyclin D1 protein and show a similar strong relationship to CDDP resistance. This would make it possible to carry out a functional assay for resistance to CDDP by extracting mRNA from tumour samples and using this to determine the relative abundance of cyclin D1 mRNA and to detect mutations in the p53 mRNA.

01ivonucl eotide Arrays: Determination of mRNA levels can be effected in a number of ways.

One can readily convert poly-A bearing mRNA to cDNA using reverse transcription - a method is described in the example illustrating this invention. Reverse Transcriptase PCR (RTPCR) methods allow the quantity of single RNAs to be determined, but with a relatively low level of accuracy. Arrays of oligonucleotides are a relatively novel approach to nucleic acid analysis, allowing mutation analysis, sequencing by hybridisation and mRNA expression analysis. Methods of construction of such arrays have been developed, ( see for example: A.C. Pease et al. Proc. Natl.

Acad. Sci. USA. 91, 5022 - 5026, 1994; U. Maskos and E.M.

Southern, Nucleic Acids Research 21, 2269 - 2270, 1993; E.M.

Southern et al, Nucleic Acids Research 22, 1368 - 1373, 1994) and further methods are envisaged. Arrays that measure expression levels of mRNAs and detect mutations in those RNAs are being developed and these offer an attractive embodiment of the diagnostic test proposed by this invention.

Immunocytochemi s try: An alternative embodiment of this invention would measure Cyclin D1 protein levels by immunocytochemistry using confocal laser fluorescence microscopy. Preferrably a scanning system would be used such as those described in PCT/US91/09217, PCT/NL/00081 and PCT/US95/01886. Additionally, it is desirable that the microscopy system should also be able to analyse multiple fluorescent dyes.

Antibodies against mutant forms of p53 would be labelled with one dye, an antibody against cyclin D1 (sc-6281, Santa Cruz Biotechnology, CA) would be labelled with a second dye whilst a third DNA binding dye could be used to select for aneuploid cells. DNA binding dyes such as Hoechst 33258 dye, which binds AT-rich DNA or Chromomycin A3 which binds GC-rich DNA, would be appropriate. At present not all mutant forms of p53 can be detected using antibodies, although antibodies exist against a number of known mutant forms of the p53 protein. A diagnostic test might comprise the steps of: o Extracting a biopsy of the tumour from a patient. o Optionally micro-dissecting that material to separate normal tissue from tumour material. o Preparing the biopsy material for microscopy which includes the steps of: - Labelling the biopsy material with the above fluorescently labelled antibody probes against Cyclin D1. The biopsy material may also, optionally be labelled with antibody probes against p53 mutant proteins and with a DNA binding dye.

- Separating the labelled cells from unbound labelled probes. o Placing the labelled biopsy material in a scanning confocal microscope to count cells that: - Over-express or show elevated levels of cyclin D1, i.e. are labelled with at least a threshold quantity of antibody against cyclin D1.

- Optionally, express mutant forms of p53, i.e. are labelled with at least the threshold quantity of antibodies against p53 mutants. Alternatively, p53 mutational status might be determined by analysis of the mRNA or genomic DNA as discussed above.

- Optionally, have chromosomal amplifications as detected by the intensity of fluorescence from DNA binding fluorescent dyes.

Fluorescence Activated Cell Sorting: A further embodiment of the diagnostic test could exploit Fluorescence Activated Cell Sorting (FACS). A FACS instrument separates cells in a suspension in a manner dependant on the cells being labelled with a fluorescent marker. A typical FACS device operates as follows. Cells in a suspension travelling in single file are passed through a vibrating nozzle which causes the formation of droplets containing a single cell or none at all. The droplets pass through a laser beam. Fluorescence excited from each individual cell in its droplet by the laser is measured. After the detector the stream of cells in suspension pass through an electrostatic collar which gives the droplets a surface charge. The cell carrying droplets are given a positive or negative charge. If the drop contains a cell that fluoresces with an intensity above a particular threshold, the drop gets a charge of one polarity. Unlabelled cells get a charge of the opposite polarity. The charged droplets are then deflected by an electric field and depending on their surface charge are directed into separate containers and are counted. Droplets that contain more than one cell scatter light more than individual cells which is readily detected and so these are left uncharged and enter a third disposal container. Multi-channel fluorescent detection devices have been constructed that can separate cells on the basis of labelling with multiple different fluorescent labels.

These have multiple lasers which can excite fluorescence at different frequencies and the detector will detect different emmission frequencies. A three label system would be appropriate for this test. The same labelled probes as those described above for use in a confocal scanning fluorescence microscope would be appropriate. A diagnostic test might comprise the steps of: o Extracting a biopsy of the tumour from a patient. o Optionally micro-dissecting that material to separate normal tissue from tumour material. o Disrupting intracellular adhesion to form a single cell suspension. o Labelling the suspended cells with the above fluorescently labelled probes against cyclin D1. The biopsy material may also, optionally be labelled with antibody probes against p53 mutant proteins and with a DNA binding dye. o Separating the labelled cells from unbound labelled probes. o Passing the labelled cell suspension through a FACS device to count cells that: - Over-express or show elevated levels of cyclin D1, i.e. are labelled with the anti-cyclin D1 antibody above a threshold for 'normal' expression.

Opt Optionally, express a mutant form of p53, i.e. are labelled with at least a threshold quantity of antibody against mutant forms of p53.

- Optionally, have chromosomal amplifications as detected by the intensity of fluorescence from DNA binding fluorescent dyes.

Modulation of Cyclin D1 Expression in p53 Mutant Human Cancers: A New Target for Therapy.

At present many attempts are being made to develop drugs which inhibit cyclin D1. As this molecule has a vital function in controlling the progress of normal cells through the 'start' component of the Gl/S checkpoint such inhibitors would be likely to be extremely non-selective and very toxic to normal cells. The more specific relationship of cyclin D1 to resistance to CDDP in p53 mutant human cancer cells described here provides a much more defined target for novel therapeutic agents which could potentially used in conjunction with CDDP itself an agent with a proven track record of curing many (though by no means all) cancers. This approach is based on a concept of starting with therapeutic agents which already work to some extent and using techniques such as gene targeting to enhance the efficacy of already available therapeutic agents.

In the case of patients who have mutant forms of p53, it may be possible to increase their responsiveness to CDDP by reducing levels of cyclin Dl. As mentioned above cyclin D1 inhibitors are likely to be non-selectively toxic, but if administered at low doses in conjunction with an agent such as CDDP, the combination may be more effective against tumours than either alone.

Example: Human in-vitro cell lines of different histological origin which exhibit a range of intrinsic sensitivity to cytotoxic drugs as measured by clonogenic cell survival assays, have been shown to provide appropriate models of the response of clinical tumours to chemotherapy. In particular, these cell lines exhibit the range of sensitivities to cytotoxic drugs and ionising radiation usually encountered in the clinic. These human in-vitro cancer cell lines are now widely recognised as relevant models for the clinical response of tumours to chemotherapy. Intrinsic sensitivity to cytotoxic agents is measured by clonogenic assays of a range of human cancer cell lines. It is therefore possible to identify genes whose expression and/or mutational status is related to intrinsic sensitivity to cytotoxic agents in a wide range of human in-vitro cell lines by measuring the expression of target genes and/or determining their mutational status and correlating these parameters to cell line sensitivity to cytotoxic agents. This procedure has identified genes relevant to clinical responsiveness to CDDP. Discoveries in human in vitro cell lines, such as those leading to this invention, therefore, have a strong possibility of being able to be translated into clinically useful tests for how well cancers may be expected to respond to treatment. The body of work that has been carried out to measure the clonogenic cell survival of a wide range of human in-vitro cell lines of different histology after exposure to CDDP is described below.

Materials and Methods: Cell lines and clonoqenic cell survival as says The growth characteristics clonogenic assay procedures of the 12 human in vitro cell lines used in this analysis have already been reported (Warenius et al 1994). The cell lines are listed, with their histological classification in Table 1. All are well established; many having been growing in vitro for several years.

Cell lines were either donations or purchased by our laboratories. On receipt all were grown for 5 passages to provide sufficient cells for batch storage in liquid nitrogen. During this period contamination was excluded by at least one passage in antibiotic free medium and mycoplasma testing was carried out on all lines. For clonogenic assays, cells were taken from a designated primary liquid nitrogen batch and grown for 3-6 passages until there were sufficient well-growing cells. Further batches from these cells were frozen in liquid nitrogen. Cells were routinely maintained in DMEM medium except RT112 and H322, which were grown in RPMI1640 and MGHU-1 which were grown in Ham's F12 medium. All lines were supplemented with 10% heat-inactivated fetal calf serum (HIFCS).

In order to assay CDDP sensitivity 102 - 105 cells were plated in 3 ml of Ham's F12 medium supplemented with 10% FCS in 6 well plates and incubated at 370 C in an atmosphere of 5% CO2 for 8 hours. Dilutions of 0.02 - 2.0 Zg/ml from a 1 mg/ml stock solution of CDDP (light protected) were then made and 1 ml of the appropriate dilution were added to each plate to give a final volume of 4 ml. The plates were then incubated at 370 C in an atmosphere of 5% CO2 in darkness for 14 days in the presence of the CDDP. The medium was then removed, the cells were fixed in 70 W ethanol and stained with 10% Giemsa and colonies of > 100 cells counted. One 6 well plate was used for each drug dilution.

The data points from ail the assays were pooled to provide means and SEMs as shown in Figures 3a and 3b. Where no SEMs are visible, the range of the SEM lies within the magnitude of the pooled data point. A minimum of 3 separate clonogenic assays with 6 points/drug dose/assay were necessary for each cell line. CDDP cell survival was determined at the 10% clonogenic cell survival level (D0.1) by interpolation of the fitted regression curve.

Identification of mutations in the p53 sene by PCR and DNA sequencinq.

Material for PCR and DNA sequencing of p53 and Western blotting for cyclin-D1 protein, was obtained from the same liquid nitrogen batches used to provide cells for clonogenic cell survival data.

Cells were grown for up to three passages prior to being subjected to the following procedures: Nucleic Acid Isolation RNA and genomic DNA were prepared from the cell lines described here by the guanidinium isothiocyanate CsC1 gradient method (Chirgwin et al, 1979, Barraclough et al, 1987). Briefly, the cells were collected in ice-cold phosphate-buffered saline (PBS) and homogenised in guanidinium isothiocyanate buffer (4M guanidinium isothiocyanate, 50mM Tris pH 7.5, 25mM EDTA pH 8.0, 0.5% (w/v) sodium lauryl sarcosine and 8% (v/v) 2-mercaptoethanol added just prior to use. The homogenate was cleared by centrifugation at 8,000 rpm for 10 mins at 4"C (SS34 rotor, Sorvall RC-5B centrifuge) and the RNA pelleted by centrifugation of the homogenate through a cushion of 5.7M caesium chloride/0.lM EDTA at 32,000 rpm for 20hr at 20"C (TST 41.14 rotor, Kontron Centrikon T20 60 ultracentrifuge). The pellet of RNA was redissolved in 0.1k (w/v) SDS and precipitated with ethanol overnight at -20 C before quantitation.

Polymerase Chain Reaction, cDNA synthesis and nucleotide seauencinq PCR (for exons 2-8 and for exons 9-11) was performed on DNA and RNA extracted from the 18 human carcinoma cell lines. Each exon was then examined by DNA sequencing. PCR Primers were designed flanking each exon and synthesised on an Applied Biosystems 381A DNA synthesiser. Each exon was amplified separately with the exceptions of exons 2 and 3 which were amplified as a unit, and exons 9, 10 and 11 which were amplified together by reverse transcription polymerase chain reaction (RTPCR). The following primers were used: Exon 2/3 sense 5'-CCC ACT TTT CCT CTT GCA GC-3' Exon 2/3 antisense 5'-AGC CCA ACC CTT GTC CTT AC-3' Exon 4 sense 5'-CTG CTC TTT TCA CCC ATC TA-3' Exon 4 antisense 5'-GCA TTG AAG TCT CAT GGA AG-3' Exon 5 sense 5'-TGT TCA CTT GTG CCC TGA CT-3' Exon 5 antisense 5'-CAG CCC TGT CGT CTC TCC AG-3' Exon 6 sense 5'-GCC TCT GAT TCC TCA CTG AT-3' Exon 6 antisense 5'-TTA ACC CCT CCT CCC AGA GA-3' Exon 7 sense 5'-ACT GGC CTC ATC TTG GGC CT-3' Exon 7 antisense 5'-TGT GCA GGG TGG CAA GTG GC-3' Exon 8 sense 5'-T ATC CTG AGT AGT GG-3' Exon 8 antisense 5'-T GCT TGC TTA CCT CG-3' Exon 9/10/11 sense 5'-AGA AAG GGG AGC CTC ACC AC-3' Exon 9/10/11 antisense 5'-CTG ACG CAC ACC TAT TGC AA-3' Genomic DNA was digested with EcoR1 and precipitated with ethanol and resuspended in 50y1 of water (Sigma) before being subjected to PCR amplification. The DNA (lung) was amplified in 50y1 PCR reactions containing 20 pmoles of each primer. A 'hot start' PCR protocol was used with the dNTP's and Taq enzyme initially separated from the rest of the reaction components on a wax cushion. The reactions were placed in a pre-heated PCR block at 95"C for 2 minutes before undergoing thirty cycles of denaturation (30s at 950C), annealing (30s at 600C for exons 2-3, 4 and 6; 65"C for exons 5 and 8; 67"C for exon 7; and 68"C for exon 9-11) and extension (1 min at 72"C). The PCR products were checked on a 0.8k (w/v) agarose gel before being purified using a wizard minicolumn (Promega), and used directly in sequencing reactions. cDNA synthesis and RTPCR Complementary DNA was synthesised from approximately 5yg of total RNA using oligo (dT) as a primer. Total RNA (5sag), human placental ribonuclease inhibitor (HPRI) 20U and lHg oligo (dT) were heated at 700C for 10 minutes, chilled on ice, added to lx first strand buffer (50mM Tris-HC1, pH 8.3, 75mM potassium chloride and 3mM magnesium chloride), 0.01M DTT, dNTPs (0.5mM for each deoxyribonucleoside triphosphate), 400U of Superscript Reverse Transcriptase (Gibco) and incubated at 37CC for 1 hour.

PCR for exons 9 to 11 was carried out using 5y1 of the above incubation in a 50y1 of PCR reaction as described in the previous section.

Nucleotide SeQuencinq Sequencing primers (10 pmoles) were radioactively labelled at their 5' ends with 32P-ATP (454Ci) at 37 C for 30 min in a reaction containing T4 Polynucleotide Kinase (PNK) (9.7U, Pharmacia) and lx T4 PNK buffer (lOmM Tris-acetate, 10mM magnesium acetate and 50mM potassium acetate). The primers used were identical to those employed in the PCR reactions except for exon 5 for which a separate sense sequencing primer was designed as follows:- 5'-TAC TCC CCT GCC CTC-3'. Sequencing was carried out by the dideoxynucleotide enzymatic method (Sanger et al, 1977), using the fmol DNA Sequencing System (Promega) . Any putative sequence mutations identified were confirmed by additional sequencing of the exon in the antisense direction as well as by carrying out a repeat PCR and sequencing of the cell line.

Western Blotting for Cvclin D1.

Two independent Western blottings with lysates for each cell line loaded in pairs on each gel were carried out. Standard conditions were used for the preparation of cells for lysates for Western blotting on each of the 16 cell lines; 107 cells were grown in 162 cm2 tissue culture flasks (Costar Ltd., High Wycombe, Bucks) until they were pre-confluent but still growing exponentially as confirmed by flow cytometry. Cells were then removed by trypsinisation, resuspended in complete medium + 10% FCS and washed 3 times by serial centrifugation and resuspension in PBS without serum. 1-3 x 108 viable cells were then pelletted by centrifugation and resuspended at 3x107 cells per ml of lysate buffer (Stock solution: 10% SDS 10ml., 0.5M Tris pH 6.8, glycerol 10 ml., Double distilled water 62 ml. To 10 ml. of stock solution were added 100 ml of 10 mM Leupeptin + 10 ml 100 mM PMSF).

Protein estimations were performed and the final concentration of the lysates adjusted to 300 Ug total cellular protein per 100 pl. To measure cyclin D1</RT 1997). In order to compare different cyclin D1 protein levels between the cell lines, the mean O.D. value for all the lines was calculated and the relative O.D. for cyclin D1 protein in each individual cell line was normalised to the mean O.D. and multiplied by an arbitrary value of 5.0.

Results: Mutations were found in mRNA expressed from the p53 gene in 7 of the 12 cell lines. The mutations identified in the cell lines described here were in exons 5-8 which are known to contain the majority of p53 mutations (Hollstein et al, 1991). All these mutations have been previously described apart from the nonsense mutation identified in codon 166 of the RPMI7951 line. This along with the G to T transversion in codon 298 of H417 did not lie within the most highly conserved region of the p53 gene. In the OAW42 ovarian carcinoma cell line the single base missense mutation from CGA to CGG was silent, so that the mutant triplet still coded for the same amino acid (Arg) as is present in wildtype p53 (wtp53) protein (Fig.lA) . A normal p53 protein was thus expressed in 6 of the 12 cell lines. The mRNA of the other 6 cell lines coded for abnormal p53 protein. RPMI7951 and H417 possessed stop mutations resulting in 165 and 297 amino acid truncated proteins respectively. COLO320 and H322 independently exhibited a missense G:C to A:T mutation at the same site resulting in an amino-acid substitution from Arg to Tryp. RT112 and HT29/5 also had mutations coding for changes in Arg (to Gly and His respectively). COLO320, H322 and RT112 were homozygous for p53 mutations. The other three mutant lines showed evidence of retention of heterozygosity (as shown for H417 in Fig.lB).

HT29/5 and RPMI7951 both expressed small amounts of wild-type p53 mRNA though H417 expressed relatively high levels.

The relationship between cyclin D1 levels and CDDP sensitivity was examined for all 12 cell lines and then independently in the wtp53 and mp53 cells. The ranges of cyclin-D1 protein levels in wtp53 cells and mp53 cells overlapped (3.33 - 10.39 and 3.58 8.46 respectively). Only in p53 mutant cells was a useful correlation found between cyclin D1 protein levels and resistance to CDDP.

Conclusions: In mutant p53 cell lines, the higher the cyclin D1 levels, the more likely it is that the cells are resistant to CDDP (Fig. 1A).

References: Barraclough et al, J. Cell Physiolog 131: 393 - 401, 1987.

Chirgwin et al, Biochemistry 18: 5294 - 5299, 1979.

Maskos and Southern, Nucleic Acids Research 21, 2269 - 2270, 1993.

Pease et al. Proc. Natl. Acad. Sci. USA. 91, 5022 - 5026, 1994.

Sanger et al, Proc. Natl. Acad. Sci. USA 74: 5463 - 5467, 1977.

Southern et al, Nucleic Acids Research 22, 1368 - 1373, 1994.

Warenius et al., Int.J.Cancer. 67: 224 - 231, 1996.

Bristow et al., Oncogene 9: 1527 - 1536, 1994.

Bristow et al., Radiotherapy and Oncology 40: 197 - 223, 1996.

P. W. G. Browning, "Proto-oncogene expression and intrinsic radiosensitivity, PhD Thesis, University of Liverpool, 1997.

Deacon et al, Radiotherapy and Oncology 2, 317 - 323, 1984.

Fan et al, Cancer Res. 54: 5824 -5830, 1994.

Fertil & Malaise, Int. J. Radiat. Oncol. Biol. Phys. 7: 621 629, 1981.

FitzGerald et al, Radiat. Res. 122: 44 - 52, 1990.

Hollstein et al, Science 253: 49 - 53, 1991.

Iliakis et al., Cancer Res. 50: 6575 - 6579, 1990.

Kasid et al., Cancer Res. 49: 3396 - 3400, 1989.

Kastan et al, Cancer Res. 51: 6304 - 6311, 1991.

Kawashima et al., Int. J. Cancer 61: 76 - 79, 1995.

Kelland et al, Radiat. Res. 116: 526 - 538, 1988 Lee and Bernstein, Proc. Natl. Acad. Sci. USA 90: 5742 - 5746, 1993.

McIlwrath et al., Cancer Res. 54: 3718 - 3722, 1994.

McKenna et al., Cancer Res. 50: 97 - 102, 1990.

McKenna et al., Radiat. Res. 125: 283 - 287, 1991 Nunez et al, Br. J. Cancer 71: 311 - 316, 1995 Pardo et al., Radiat. Res. 140: 180 - 185, 1994 Pirollo et al., Int. J. Radiat. Biol. 55: 783 - 796, 1989 Pirollo et al., Radiat. Res. 135: 234 - 243, 1993.

Powell & McMillan, Int. J. Rad. Oncol. Biol. Phys., 29: 1035 1040, 1994.

Radford, Int. J. Radiat. Biol. 66: 557 - 560, 1994.

Sanger et al, Proc. Natl. Acad. Sci. USA 74: 5463 - 5467, 1977.

Schwartz et al., Int. J. Radiat. Biol. 59: 1314 - 1352, 1991.

Shimm et al., Radiat. Res. 129: 149 - 156, 1992.

Siles et al., Br. J. Cancer 73: 581 - 588, 1996.

Su & Little, Int. J. Radiat. Biol. 62: 461 - 468, 1992.

Su & Little, Radiat. Res. 133: 73 - 79, 1993.

Suzuki et al., Radiat. Res. 129: 157 - 162, 1992.

Warenius et al., Eur. J. Cancer 30, 369 - 375, 1994.

Warenius et al., Rad. Research 146,485 - 493, 1996.

Whitaker et al., Int. J. Radiat. Biol. 67: 7 - 18, 1995.

Xia et al., Cancer Res. 55: 12 - 15, 1995.

Zhen et al., Mut. Res. 346, 85 - 92, 1995.

Claims (28)

1. CLAIMS: 1. A method for measuring the resistance of p53 mutant cancer cells to the cytotoxic effects of chemotherapeutic agents, which method comprises testing a sample comprising p53 mutant cells or an extract therefrom for the abundance of cyclin D1 protein.
2. 2. A method according to claim 1, wherein the sample is extracted from a subject.
3. 3. A method according to claim 1 or claim 2, wherein the chemotherapeutic agent is a platination agent.
4. 4. A method according to claim 3, wherein the platination agent is CDDT.
5. 5. A method according to any preceding claim, wherein the testing for the abundance of cyclin D1 protein comprises measuring the abundance of cyclin D1 mRNA.
6. 6. A method according to claim 5, wherein the measurement of the abundance of cyclin D1 mRNA comprises contacting the sample with a probe for cyclin D1 mRNA.
7. 7. A method according to any of claims 1-4, wherein the testing is carried out using Western blotting.
8. 8. A method according to any of claims 1-4, wherein the testing comprises contacting the sample with a labelled antibody against cyclin D1 protein
9. 9. A method according to claim 8, wherein the antibody against cyclin D1 protein is 14841 C (from clone number G-124-259.5, Pharmingen USA).
10. 10. A method according to any preceding claim, wherein p53 mutant cells are identified by contacting the sample with a labelled antibody against mutant p53.
11. 11. A method according to any of claims 8-10, wherein at least one antibody is labelled with a fluorescent label.
12. 12. A method according to any preceding claim, further comprising contacting the sample with a DNA binding dye for labelling aneuploid cells.
13. 13. A method according to claim 12, wherein the DNA binding dye is Hoechst 33258, or Chromomycin A3 dye.
14. 14. A method according to any preceding claim1 wherein the sample is a sample of cells.
15. 15. A method according to claim 14, wherein the testing is carried out by performing a cell count.
16. 16. A method according to claim 15, wherein the cell count is performed using multi-parameter flow cytometry.
17. 17. A method according to claim 15, wherein the cell count is performed using scanning confocal microscopy.
18. 18. A method according to claim 15, wherein the cell count is performed using fluorescence activated cell sorting.
19. 19. A method according to any of claims 15-18, wherein the sample of cells is micro-dissected prior to performing the cell count, to separate normal tissue from tumour tissue.
20. 20. A method according to any of claims 15-19, wherein prior to performing the cell count, intracellular adhesion in the sample of cells is disrupted, to form a single cell suspension.
21. 21. A kit for measuring the resistance of p53 mutant cancer cells to the cytotoxic effects of chemotherapeutic agents, which method comprises a means for testing for the abundance of cyclin D1 protein and a means for identifying p53 mutant cells.
22. 22. A kit according to claim 21, wherein the means for testing for the abundance of cyclin D1 protein comprises a probe for cyclin D1 mRNA.
23. 23. A kit according to claim 21, wherein the means for testing for the abundance of cyclin D1 protein comprises a labelled antibody against cyclin D1 protein.
24. 24. A kit according to claim 23, wherein the antibody against cyclin D1 protein is 14841 C (from clone number G-124-259.5, Pharmingen USA).
25. 25. A kit according to any of claims 21-24, wherein the means for identifying p53 mutant cells comprises a labelled antibody against mutant p53.
26. 26. A kit according to any of claims 23-25, wherein at least one antibody is labelled with a fluorescent label.
27. 27. A kit according to any of claims 21-26, further comprising a DNA binding dye, for labelling aneuploid cells.
28. 28. A kit according to claim 27, wherein the DNA binding dye is Hoechst 33258, or Chromomycin A3 dye.